Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1988 1
1989 11
1990 16
1991 37
1992 45
1993 119
1994 194
1995 265
1996 352
1997 368
1998 434
1999 521
2000 630
2001 676
2002 707
2003 750
2004 751
2005 762
2006 745
2007 803
2008 817
2009 762
2010 704
2011 734
2012 720
2013 670
2014 686
2015 712
2016 610
2017 560
2018 527
2019 514
2020 427
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

15,258 results
Results by year
Filters applied: . Clear all
Page 1
The Immune Revolution: A Case for Priming, Not Checkpoint.
Vonderheide RH. Vonderheide RH. Cancer Cell. 2018 Apr 9;33(4):563-569. doi: 10.1016/j.ccell.2018.03.008. Cancer Cell. 2018. PMID: 29634944 Free PMC article. Review.
CD40 activation plays a critical role in generating T cell immunity, by activating dendritic cells, and converting cold tumors to hot. ...With the advent of multiple CD40 agonists with acceptable single-agent toxicity, clinical evaluation of CD40 combinations
CD40 activation plays a critical role in generating T cell immunity, by activating dendritic cells, and converting cold tumors to hot
Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond.
Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Karnell JL, et al. Adv Drug Deliv Rev. 2019 Feb 15;141:92-103. doi: 10.1016/j.addr.2018.12.005. Epub 2018 Dec 13. Adv Drug Deliv Rev. 2019. PMID: 30552917 Free article. Review.
CD40 is a TNF receptor superfamily member expressed on both immune and non-immune cells. Interactions between B cell-expressed CD40 and its binding partner, CD40L, predominantly expressed on activated CD4+ T cells, play a critical role in promoting germinal center f
CD40 is a TNF receptor superfamily member expressed on both immune and non-immune cells. Interactions between B cell-expressed CD4
CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
Argiriadi MA, Benatuil L, Dubrovska I, Egan DA, Gao L, Greischar A, Hardman J, Harlan J, Iyer RB, Judge RA, Lake M, Perron DC, Sadhukhan R, Sielaff B, Sousa S, Wang R, McRae BL. Argiriadi MA, et al. BMC Mol Cell Biol. 2019 Aug 5;20(1):29. doi: 10.1186/s12860-019-0213-4. BMC Mol Cell Biol. 2019. PMID: 31382872 Free PMC article.
The involvement of CD40 in chronic immune activation has resulted in CD40 being proposed as a therapeutic target for a range of chronic inflammatory diseases. ...RESULTS: To better understand the mode of action of anti-CD40 mAbs, we have determined the x-ray …
The involvement of CD40 in chronic immune activation has resulted in CD40 being proposed as a therapeutic target for a range o …
Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA, Thomas LJ, He LZ, O'Neill T, Widger J, Crocker A, Sundarapandiyan K, Storey JR, Forsberg EM, Weidlick J, Baronas AR, Gergel LE, Boyer JM, Sisson C, Goldstein J, Marsh HC Jr, Keler T. Vitale LA, et al. Cancer Immunol Immunother. 2019 Feb;68(2):233-245. doi: 10.1007/s00262-018-2267-0. Epub 2018 Oct 31. Cancer Immunol Immunother. 2019. PMID: 30382327
This naturally occurs through interaction with CD40 ligand (CD40L) expressed on CD4(+) T-helper cells. CD40 signaling can also be achieved using specific antibodies, leading to several agonist CD40 antibodies entering clinical development. ...CDX-1140 is a hu …
This naturally occurs through interaction with CD40 ligand (CD40L) expressed on CD4(+) T-helper cells. CD40 signaling can also …
Agonistic CD40 antibodies and cancer therapy.
Vonderheide RH, Glennie MJ. Vonderheide RH, et al. Clin Cancer Res. 2013 Mar 1;19(5):1035-43. doi: 10.1158/1078-0432.CCR-12-2064. Clin Cancer Res. 2013. PMID: 23460534 Free PMC article.
Agonistic CD40 monoclonal antibodies (mAb) offer a new therapeutic option which has the potential to generate anticancer immunity by various mechanisms. ...Thus, agonistic CD40 mAb are fundamentally different from mAb which block negative immune checkpoint such as a …
Agonistic CD40 monoclonal antibodies (mAb) offer a new therapeutic option which has the potential to generate anticancer immunity by …
The Use of Anti-CD40 mAb in Cancer.
Remer M, White A, Glennie M, Al-Shamkhani A, Johnson P. Remer M, et al. Curr Top Microbiol Immunol. 2017;405:165-207. doi: 10.1007/82_2014_427. Curr Top Microbiol Immunol. 2017. PMID: 25651948 Review.
Anti-CD40 mAb therapy acts via multiple mechanisms to stimulate anti-tumour immunity across a broad range of lymphoid and solid malignancies. A wealth of preclinical research in this field has led to the successful development of multiple anti-CD40 mAb agents that h …
Anti-CD40 mAb therapy acts via multiple mechanisms to stimulate anti-tumour immunity across a broad range of lymphoid and solid malig …
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O'Brien L, Mockridge CI, French RR, Duriez P, Douglas LR, Pearson AR, Cragg MS, Tews I, Glennie MJ, White AL. Yu X, et al. Cancer Cell. 2018 Apr 9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22. Cancer Cell. 2018. PMID: 29576376 Free PMC article.
Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function hold promise as therapeutics for cancer and autoimmunity. ...In addition, all CRD2-4 binding mAbs blocked CD40 ligand interaction and were potent antagonists. Thus, the membrane distal …
Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function hold promise as therapeutics for cancer and autoimmu …
Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome.
Meng X, Yang B, Suen WC. Meng X, et al. Innate Immun. 2018 Jan;24(1):4-10. doi: 10.1177/1753425917739681. Epub 2017 Nov 13. Innate Immun. 2018. PMID: 29132233 Free PMC article. Review.
Interruption of the CD40/CD40L signal causes hyper-IgM (HIGM) syndrome, which has been classified and recognized as a group of rare inherited immune deficiency disorders. ...Modifying the CD40/CD40L signaling pathway may offer the possibility of restoring the normal …
Interruption of the CD40/CD40L signal causes hyper-IgM (HIGM) syndrome, which has been classified and recognized as a group of rare i …
Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody.
Ristov J, Espie P, Ulrich P, Sickert D, Flandre T, Dimitrova M, Müller-Ristig D, Weider D, Robert G, Schmutz P, Greutmann B, Cordoba-Castro F, Schneider MA, Warncke M, Kolbinger F, Cote S, Heusser C, Bruns C, Rush JS. Ristov J, et al. Am J Transplant. 2018 Dec;18(12):2895-2904. doi: 10.1111/ajt.14872. Epub 2018 May 24. Am J Transplant. 2018. PMID: 29665205 Free article.
The CD40-CD154 costimulatory pathway is essential for T cell-dependent immune responses, development of humoral memory, and antigen presenting cell function. ...We also established a relationship between plasma concentrations of CFZ533 and CD40 pathway-relevant phar …
The CD40-CD154 costimulatory pathway is essential for T cell-dependent immune responses, development of humoral memory, and antigen p …
[CD40].
[No authors listed] [No authors listed] Arerugi. 2017;66(2):118-119. doi: 10.15036/arerugi.66.118. Arerugi. 2017. PMID: 28331104 Japanese. No abstract available.
15,258 results
Jump to page
Feedback